SG11201809086YA - Treatment of liver, biliary tract and pancreatic disorders - Google Patents
Treatment of liver, biliary tract and pancreatic disordersInfo
- Publication number
- SG11201809086YA SG11201809086YA SG11201809086YA SG11201809086YA SG11201809086YA SG 11201809086Y A SG11201809086Y A SG 11201809086YA SG 11201809086Y A SG11201809086Y A SG 11201809086YA SG 11201809086Y A SG11201809086Y A SG 11201809086YA SG 11201809086Y A SG11201809086Y A SG 11201809086YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- treatment
- rule
- liver
- pct
- Prior art date
Links
- 208000016222 Pancreatic disease Diseases 0.000 title abstract 3
- 210000003445 biliary tract Anatomy 0.000 title abstract 3
- 210000004185 liver Anatomy 0.000 title abstract 3
- 208000015163 Biliary Tract disease Diseases 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 102000000541 Defensins Human genes 0.000 abstract 2
- 108010002069 Defensins Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670276 | 2016-04-29 | ||
| DKPA201670484 | 2016-07-01 | ||
| PCT/DK2017/050132 WO2017186250A1 (en) | 2016-04-29 | 2017-04-28 | Treatment of liver, biliary tract and pancreatic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809086YA true SG11201809086YA (en) | 2018-11-29 |
Family
ID=58992579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809086YA SG11201809086YA (en) | 2016-04-29 | 2017-04-28 | Treatment of liver, biliary tract and pancreatic disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12076368B2 (pt) |
| EP (1) | EP3448409A1 (pt) |
| JP (1) | JP2019514908A (pt) |
| KR (1) | KR102465341B1 (pt) |
| CN (1) | CN109414474B (pt) |
| AU (1) | AU2017258242B2 (pt) |
| BR (1) | BR112018071972A2 (pt) |
| CA (1) | CA3022497A1 (pt) |
| RU (1) | RU2740913C2 (pt) |
| SG (1) | SG11201809086YA (pt) |
| WO (1) | WO2017186250A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| SG11202107310RA (en) | 2019-01-07 | 2021-08-30 | Aesculus Bio Aps | Defensin fragments for use in therapy or prophylaxis |
| CN110279851A (zh) * | 2019-07-05 | 2019-09-27 | 浙江大学 | Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用 |
| CN114058694A (zh) * | 2021-11-29 | 2022-02-18 | 上海市普陀区中心医院 | Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用 |
| KR20240068432A (ko) * | 2022-11-10 | 2024-05-17 | 을지대학교 산학협력단 | 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| WO2003101394A2 (en) | 2002-05-31 | 2003-12-11 | Ciphergen Biosystems, Inc. | Defensins: use as antiviral agents |
| US7528107B2 (en) | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2007081486A2 (en) | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
| US20100104529A1 (en) | 2006-05-01 | 2010-04-29 | England Robert L | TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha |
| JP2009541287A (ja) * | 2006-06-20 | 2009-11-26 | リポペプチド・アクチエボラーグ | 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用 |
| WO2008115390A2 (en) * | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
| RU2010136023A (ru) | 2008-02-01 | 2012-03-10 | Асцендис Фарма Ас (Dk) | Пролекарство, содержащее саморасщепляемый линкер |
| EA201170219A1 (ru) * | 2008-07-18 | 2011-08-30 | Новозимс Эдениум Байотек А/С | Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих |
| KR20110031962A (ko) | 2008-07-18 | 2011-03-29 | 노보자임스 아데니움 바이오테크 에이/에스 | 포유류 베타 방어소를 이용한 염증 질환의 치료 |
| EP2396347B1 (en) | 2009-02-11 | 2017-04-12 | Albumedix A/S | Albumin variants and conjugates |
| US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| US20110311601A1 (en) | 2010-06-22 | 2011-12-22 | Michael Kleine | Antimicrobial medical devices |
| DE102010040153A1 (de) | 2010-09-02 | 2012-03-08 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen |
| CN103906528A (zh) * | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
| WO2013006692A2 (en) * | 2011-07-06 | 2013-01-10 | The General Hospital Corporation | Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) |
| ES2637286T3 (es) * | 2011-07-08 | 2017-10-11 | Defensin Therapeutics Aps | Tratamiento oral de la enfermedad inflamatoria intestinal |
| WO2013026794A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes | Novel immunomodulatory peptide |
| CN104736558A (zh) * | 2012-09-07 | 2015-06-24 | 赛诺菲 | 用于治疗代谢综合征的融合蛋白 |
| CN104971343B (zh) * | 2015-07-13 | 2018-02-02 | 韩源平 | 防御素在制备治疗代谢综合征药物方面的应用 |
| CN105504063B (zh) * | 2015-10-19 | 2019-10-01 | 中国医学科学院医药生物技术研究所 | 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用 |
| KR20180121489A (ko) | 2016-01-26 | 2018-11-07 | 디펜신 테라퓨틱스 에이피에스 | 장내 미생물을 조절하는 방법 |
| US11040996B2 (en) * | 2016-07-30 | 2021-06-22 | Bontac Bio-Engineering(Shenzhen) Co., Ltd | Method for preparing nicotinamide mononucleotide (NMN) |
| CN114075585A (zh) * | 2020-08-18 | 2022-02-22 | 弈柯莱生物科技(上海)股份有限公司 | 一种β-烟酰胺单核苷酸的制备方法 |
| CN112795606B (zh) * | 2021-04-14 | 2021-07-27 | 深圳瑞德林生物技术有限公司 | 一种β-烟酰胺单核苷酸的酶催化合成方法 |
| CN114107160A (zh) * | 2021-12-27 | 2022-03-01 | 浙江工业大学 | 一种烟酰胺核糖激酶基因工程菌及其应用 |
-
2017
- 2017-04-28 CA CA3022497A patent/CA3022497A1/en active Pending
- 2017-04-28 WO PCT/DK2017/050132 patent/WO2017186250A1/en active Search and Examination
- 2017-04-28 JP JP2018556275A patent/JP2019514908A/ja not_active Ceased
- 2017-04-28 AU AU2017258242A patent/AU2017258242B2/en not_active Expired - Fee Related
- 2017-04-28 EP EP17727094.9A patent/EP3448409A1/en active Pending
- 2017-04-28 US US16/097,072 patent/US12076368B2/en active Active
- 2017-04-28 BR BR112018071972-2A patent/BR112018071972A2/pt not_active IP Right Cessation
- 2017-04-28 SG SG11201809086YA patent/SG11201809086YA/en unknown
- 2017-04-28 KR KR1020187033643A patent/KR102465341B1/ko active IP Right Grant
- 2017-04-28 CN CN201780039341.1A patent/CN109414474B/zh active Active
- 2017-04-28 RU RU2018141326A patent/RU2740913C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017258242B2 (en) | 2024-04-04 |
| AU2017258242A1 (en) | 2018-11-29 |
| US20190192626A1 (en) | 2019-06-27 |
| WO2017186250A1 (en) | 2017-11-02 |
| RU2018141326A (ru) | 2020-05-29 |
| CN109414474A (zh) | 2019-03-01 |
| BR112018071972A2 (pt) | 2019-02-26 |
| CA3022497A1 (en) | 2017-11-02 |
| RU2018141326A3 (pt) | 2020-08-06 |
| RU2740913C2 (ru) | 2021-01-21 |
| US12076368B2 (en) | 2024-09-03 |
| KR20190003592A (ko) | 2019-01-09 |
| CN109414474B (zh) | 2024-07-02 |
| KR102465341B1 (ko) | 2022-11-09 |
| JP2019514908A (ja) | 2019-06-06 |
| EP3448409A1 (en) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201809086YA (en) | Treatment of liver, biliary tract and pancreatic disorders | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11202000136YA (en) | Preparation comprising vonoprazan | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201811221XA (en) | Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |